Regeneron, Sanofi Get FDA Approval For Dupixent in Allergic Fungal Rhinosinusitis
Regeneron, Sanofi Get FDA Approval For Dupixent in Allergic Fungal Rhinosinusitis is drawing significant interest across the industry.
By Colin Kellaher Regeneron Pharmaceuticals and Sanofi have won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Sam Thompson admits to 'super tough' few days as he shares health update after he was left unable to speak following vocal cord surgery
- Why isn't the Mass. governor talking about climate challenges?
- POVA Curve 2 Goes Official with Massive Battery Power in a Slim, Futuristic Design
- Calls for arena expansion from Greater Napanee residents
Source: Original →